Tag:
Presage Biosciences
Latest Headlines
Latest Headlines
Celgene drops $13M on Presage's 3-D drug delivery platform
Celgene's $13 million investment in Presage Biosciences' cancer drug delivery platform is a major bet on something groundbreaking. The technology is the first of its kind, with the ability to compare treatments across separate sections of a tumor.
Celgene buys into upstart's new approach to picking cancer combos
Fast-moving Celgene has turned to Presage Biosciences to begin testing the potential of cancer drug combinations in animals, paying $5 million upfront to support the research and taking an $8 million equity stake in the up-and-coming biotech.
Seattle start-up attracts early adopters of cancer drug tech
Presage Biosciences in Seattle reports that it is gaining some significant traction for its new approach to testing cancer drugs in mice. The Seattle-based biotech tells Xconomy that it has boosted
